INSTIL BIO INC (TIL)
US45783C2008 - Common Stock
TIL Stock Earnings: Instil Bio Beats EPS for Q4 2023
TIL stock results show that Instil Bio beat analyst estimates for earnings per share the fourth quarter of 2023.
TIL Stock Earnings: Instil Bio Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Instil Bio (NASDAQ:TIL) just reported results for the fourth quarter of 2023.In...
Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a...
Instil Bio stock hits four-month high (NASDAQ:TIL)
Instil Bio (TIL) stock surged 21% on Wednesday after the biotech announced cost-cutting measures and a new partnership for its ITIL-306 program. Read more here.
Instil Bio Announces Strategic Update
Instil Bio Announces Strategic Update
DALLAS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused...
TIL Stock Earnings: Instil Bio Misses EPS for Q1 2023
TIL stock results show that Instil Bio missed analyst estimates for earnings per share the first quarter of 2023.
TIL Stock Earnings: Instil Bio Misses EPS for Q1 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Instil Bio (NASDAQ:TIL) just reported results for the first quarter of 2023.Ins...
TIL Stock Earnings: Instil Bio Beats EPS for Q2 2023
TIL stock results show that Instil Bio beat analyst estimates for earnings per share the second quarter of 2023.
TIL Stock Earnings: Instil Bio Beats EPS for Q2 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Instil Bio (NASDAQ:TIL) just reported results for the second quarter of 2023.In...
TIL Stock Earnings: Instil Bio Misses EPS for Q3 2023
TIL stock results show that Instil Bio missed analyst estimates for earnings per share the third quarter of 2023.
TIL Stock Earnings: Instil Bio Misses EPS for Q3 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Instil Bio (NASDAQ:TIL) just reported results for the third quarter of 2023.Ins...
Instil Bio announces effective date of 1-for-20 reverse stock split (NASDAQ:TIL)
Instil Bio announces a 1-for-20 reverse stock split effective December 7th, aiming to regain compliance with Nasdaq's minimum bid price requirement.
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
DALLAS, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused...
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
DALLAS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing...
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
Presented novel preclinical data showing that CoStAR enhances activity of CD4+ T cells in multiple ways to broaden anti-tumor response and support CD8+ T cells
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
ITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023 Initial data from ITIL-306-202 clinical...
Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference
Presented data showing that folate receptor α (FRα)-CoStAR enhanced activity of TILs against autologous NSCLC, ovarian, and renal tumors ITIL-306, first...
Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Instil confirms cash runway beyond 2026 ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H'2023 Anticipate initial clinical...
NASDAQ:TIL Shareholder Notice: Investigation over Potential Wrongdoing at Instil Bio, Inc.
San Diego, CA -- (SBWIRE) -- 02/10/2023 -- Certain directors of Instil Bio, Inc. are under investigation over potential breaches of fiduciary duties.
Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site
Company anticipates cash resources to provide runway beyond 2026 Initial clinical data from the ITIL-306 program expected in 2023 Instil is consolidating...
Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer
Phase 1 trial of ITIL-306 in NSCLC, ovarian, and RCC re-opened to enrollment after voluntary pause Initial data readout for ITIL-306 expected in 2023 ...
Thursday Sector Leaders: Biotechnology, Drugs